

# **PRESS RELEASE**



## **Dr. Swarna Balasubramaniam Joins Siva As a Medical Adviser**

AUSTIN, TEXAS, June 10, 2021 – Siva Therapeutics (“Siva”) is pleased to announce that Dr. Swarna Balasubramaniam has joined Siva as a Medical Adviser.

Dr. Swarna Balasubramaniam is an experienced Colon and Rectal surgeon and also the founder of a medical device start-up Noleus Technologies. She received her undergraduate degree in Chemistry from Wellesley College, her M.D. from Mayo Clinic School of Medicine. She trained in General Surgery at the Mayo Clinic in Rochester, MN and completed a fellowship in Colon & Rectal Surgery at the University of Southern California and has been in practice for more than 20 years. Dr. Balasubramaniam has a keen interest in oncology and completed 2 years of molecular oncology research during surgical training and colorectal cancer patients constituted a large proportion of her clinical surgical practice.

Siva has identified treatment of colorectal cancers as an important initial clinical indication due to unmet need, large market, and the ability to integrate Siva’s Targeted Hyperthermia™ into clinical workflows. Treating colorectal cancers early with Targeted Hyperthermia™ promises to reduce the extent of surgery and to result in better outcomes for patients.

“We’re delighted to have Dr. Balasubramaniam advise Siva.” said Len Pagliaro, PhD, CEO of Siva. “Her depth and breadth of experience with colorectal cancer and colorectal cancer surgery, and her entrepreneurial experience bring great value to our team. We look forward to having Swarna work with us as we move toward the clinic.”



### **About Siva Therapeutics, Inc.**

Siva Therapeutics Inc is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancers. The heat is delivered to tumors by infrared light that is absorbed by SivaRods™ gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (44°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion – thus enabling drugs to reach all tumor compartments more effectively. The size, shape, and surface chemistry of the nanorods target the leaky vasculature of solid tumors, and the selective thermal sensitivity of tumor tissue enables the therapy to deliver clean margins. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments. Siva’s initial clinical targets include colorectal, pancreatic, and esophageal cancers.

Contact us at [info@sivatherapeutics.com](mailto:info@sivatherapeutics.com) or visit: [www.sivatherapeutics.com](http://www.sivatherapeutics.com)